Carlos M. Gastalho

Mr. Carlos M. Gastalho

University of Évora, Évora, Portugal
orcid
MsC | PharmD. | PhD Fellow (@FCT)

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2022 in Synthesis
Verified
Journal Article
Closed access
PDF file
Elisabete P. CarreiroElisabete P. Carreiro
Elisabete P. Carreiro
Carlos M. GastalhoCarlos M. Gastalho
Carlos M. Gastalho
SESofia Ernesto
Sofia Ernesto
ACAna R. Costa
Ana R. Costa
CACélia M. Antunes
Célia M. Antunes
Anthony BurkeAnthony Burke
Anthony Burke
Twenty-three new quercetin-1,2,3-triazole hybrids were synthesized in good to quantitative yields via Cu(I)-catalyzed azide-alkyne cycloaddition reaction under microwave irradiation. These new hybrids contain a 1,4-disubstituted 1,2,3-triazole ring at the 3-OH position of quercetin whilst the remaining hydroxyl groups were either protected as methyl or benzyl groups or left unprotected. All the quercetin-1,2,3-triazole hybrids I–IV were evaluated against REM-134 canine mammary cancer cell line, which is used as a translational model for human breast cancer. These new analogues exhibit potent antiproliferative activity against this cancer cell line. Furthermore, the results show that some of the new quercetin-1,2,3-triazole hybrids have better activity than quercetin. Our best inhibitors displayed IC50 values in the range of 41–180 nM, and undoubtedly will have an important impact on the treatment of both canine and human breast cancer. Received: 16 February 2022 Accepted after revision: 22 April 2022 Article published online: 08 June 2022 © 2022. Thieme. All rights reserved Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Verified
Journal Article
Open access
PDF file
Carlos M. GastalhoCarlos M. Gastalho
Carlos M. Gastalho
ASAna Margarida Ribeiro Sena
Ana Margarida Ribeiro Sena
Óscar LópezÓscar López
Óscar López
JFJosé G. Fernadez-Bolanos
José G. Fernadez-Bolanos
Alfonso T. Garcia-SosaAlfonso T. Garcia-Sosa
Alfonso T. Garcia-Sosa
Elisabete P. CarreiroElisabete P. Carreiro
Elisabete P. Carreiro
Combining the pharmacological properties of the 1,2,3-triazole and dihydropyrimidinone classes of compounds, two small families of mono- and di(1,2,3-triazole)-dihydropyrimidinone hybrids, A and B, were previously synthesized. The main objective of this work was to investigate the potential anti-Alzheimer effects of these hybrids. The inhibitory activities of cholinesterases (AChE and BuChE), antioxidant activity, and the inhibitory mechanism through in silico (molecular docking) and in solution (STD-NMR) experiments were evaluated. The 1,2,3-triazole-dihydropyrimidinone hybrids (A and B) showed moderate in vitro inhibitory activity on eqBuChE (IC50 values between 1 and 58.4 μM). The best inhibitor was the hybrid B4, featuring two 1,2,3-triazole cores, which exhibited stronger inhibition than galantamine, with an IC50 of 1 ± 0.1 μM for eqBuChE, through a mixed inhibition mechanism. Among the hybrids A, the most promising inhibitor was A1, exhibiting an IC50 of 12 ± 2 µM, similar to that of galantamine. Molecular docking and STD-NMR experiments revealed the key binding interactions of these promising inhibitors with BuChE. Hybrids A and B did not display Artemia salina toxicity below 100 μM.